That’s one way that Chiesi Group – an Italian family business-turned-global pharma company – seeks to define itself. A Benefit Corporation since 2018 and a Certified B-Corp since 2019 ...

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS ...

Chiesi UK & Ireland has published new research revealing significant gaps in the understanding and practice of inhaler use among UK asthma patients. The study published in the BMJ Open Respiratory ...

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $264.89.

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

The yearslong bankruptcy case could be coming to a close. Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...